{'52WeekChange': -0.037870646,
 'SandP52WeekChange': 0.0644362,
 'address1': '1551 Eastlake Avenue East',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 38,
 'askSize': 3200,
 'averageDailyVolume10Day': 2032550,
 'averageVolume': 1184258,
 'averageVolume10days': 2032550,
 'beta': None,
 'beta3Year': None,
 'bid': 35.1,
 'bidSize': 900,
 'bookValue': 4.356,
 'category': None,
 'circulatingSupply': None,
 'city': 'Seattle',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 36.55,
 'dayLow': 35.74,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -48.161,
 'enterpriseToRevenue': 43.859,
 'enterpriseValue': 4092700672,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '206 659 0667',
 'fiftyDayAverage': 43.710285,
 'fiftyTwoWeekHigh': 55.12,
 'fiftyTwoWeekLow': 15.19,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 76076733,
 'forwardEps': -1.09,
 'forwardPE': -33.330276,
 'fromCurrency': None,
 'fullTimeEmployees': 453,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0547,
 'heldPercentInstitutions': 0.73437,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/adaptivebiotech.com',
 'longBusinessSummary': 'Adaptive Biotechnologies Corporation, a '
                        'commercial-stage company, develops an immune medicine '
                        'platform for the diagnosis and treatment of various '
                        'diseases. The company offers immunoSEQ research '
                        'service and kit that is used to answer research '
                        'questions, as well as to discover new prognostic and '
                        'diagnostic signals. It also provides clonoSEQ '
                        'diagnostic tests, which include immunosequencing '
                        'services for use in the detection and monitoring of '
                        'minimal residual disease in patients with select '
                        'blood cancers. In addition, the company offers a '
                        'pipeline of clinical products and services that are '
                        'used for the diagnosing, monitoring, and treatment of '
                        'diseases, such as cancer, autoimmune conditions, and '
                        'infectious diseases. Adaptive Biotechnologies '
                        'Corporation has strategic collaborations with '
                        'Genentech, Inc. for the development, manufacture, and '
                        'commercialization of neoantigen directed T cell '
                        'therapies for the treatment of a range of cancers; '
                        'Microsoft Corporation to develop diagnostic tests for '
                        'the early detection of various diseases from a single '
                        'blood test; and Amgen to develop a therapeutic to '
                        'prevent or treat COVID-19. It serves the life '
                        'sciences research, clinical diagnostics, and drug '
                        'discovery customers. The company was formerly known '
                        'as Adaptive TCR Corporation and changed its name to '
                        'Adaptive Biotechnologies Corporation in December '
                        '2011. Adaptive Biotechnologies Corporation was '
                        'founded in 2009 and is headquartered in Seattle, '
                        'Washington.',
 'longName': 'Adaptive Biotechnologies Corporation',
 'market': 'us_market',
 'marketCap': 4658741248,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_100147173',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -82333000,
 'nextFiscalYearEnd': 1640908800,
 'open': 36.4,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -3.96,
 'phone': '206 659 0067',
 'previousClose': 37.06,
 'priceHint': 2,
 'priceToBook': 8.34022,
 'priceToSalesTrailing12Months': 49.924892,
 'profitMargins': -0.8747,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 36.55,
 'regularMarketDayLow': 35.74,
 'regularMarketOpen': 36.4,
 'regularMarketPreviousClose': 37.06,
 'regularMarketPrice': 36.4,
 'regularMarketVolume': 1181167,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 128234000,
 'sharesPercentSharesOut': 0.0225,
 'sharesShort': 2859637,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2758762,
 'shortName': 'Adaptive Biotechnologies Corpor',
 'shortPercentOfFloat': 0.0403,
 'shortRatio': 2.48,
 'startDate': None,
 'state': 'WA',
 'strikePrice': None,
 'symbol': 'ADPT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.845,
 'twoHundredDayAverage': 33.605217,
 'volume': 1181167,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.adaptivebiotech.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '98102'}